Abstract
This article focuses on the possible application of antagonists of the G-protein coupled chemokine receptor, CXCR4, for the treatment of glioblastoma and summarises the evidence for CXCR4 antagonism being a viable therapeutic approach. Particular attention is paid to the role of this receptor in cancer stem cell biology, and the maintenance of CXCR4 expression by the glioblastoma key driver mutations. The expression of the CXCR4 receptor, and of its ligand stromal derived factor 1 (SDF-1, CXCL12), is maintained by intracellular pathways via positive feedback loops, and is associated with the epithelial mesenchymal transition (EMT) and the generation and self-renewal of cancer stem cells. SDF-1 and CXCR4 also play a role in the generation and maintenance of the perivascular stem cell niche which contains these cancer stem cells. The available data suggest that most, if not all, glioblastoma cancer stem cells rely on CXCR4 mediated signalling to maintain their phenotype. SDF-1 and CXCR4 are alsoinvolved in many other aspects of brain tumour biology including resistance to radio- and chemotherapy, the migration of cancer cells through the brain, the generation of the tumour blood supply and the recruitment of vascular progenitor cells. These properties suggest that a CXCR4 antagonist would help in the control of this disease.
Keywords: Cancer stem cell, CXCL12, CXCR4, EMT, glioblastoma, SDF-1, signaling.
Anti-Cancer Agents in Medicinal Chemistry
Title:CXCR4 and Glioblastoma
Volume: 16 Issue: 1
Author(s): Peter J. Richardson
Affiliation:
Keywords: Cancer stem cell, CXCL12, CXCR4, EMT, glioblastoma, SDF-1, signaling.
Abstract: This article focuses on the possible application of antagonists of the G-protein coupled chemokine receptor, CXCR4, for the treatment of glioblastoma and summarises the evidence for CXCR4 antagonism being a viable therapeutic approach. Particular attention is paid to the role of this receptor in cancer stem cell biology, and the maintenance of CXCR4 expression by the glioblastoma key driver mutations. The expression of the CXCR4 receptor, and of its ligand stromal derived factor 1 (SDF-1, CXCL12), is maintained by intracellular pathways via positive feedback loops, and is associated with the epithelial mesenchymal transition (EMT) and the generation and self-renewal of cancer stem cells. SDF-1 and CXCR4 also play a role in the generation and maintenance of the perivascular stem cell niche which contains these cancer stem cells. The available data suggest that most, if not all, glioblastoma cancer stem cells rely on CXCR4 mediated signalling to maintain their phenotype. SDF-1 and CXCR4 are alsoinvolved in many other aspects of brain tumour biology including resistance to radio- and chemotherapy, the migration of cancer cells through the brain, the generation of the tumour blood supply and the recruitment of vascular progenitor cells. These properties suggest that a CXCR4 antagonist would help in the control of this disease.
Export Options
About this article
Cite this article as:
Richardson J. Peter, CXCR4 and Glioblastoma, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (1) . https://dx.doi.org/10.2174/1871520615666150824153032
DOI https://dx.doi.org/10.2174/1871520615666150824153032 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ceramide and Sphingosine-1-Phosphate in Cell Death Pathways : Relevance to the Pathogenesis of Alzheimer's Disease
Current Alzheimer Research Targeting Mammalian Target of Rapamycin: Prospects for the Treatment of Inflammatory Bowel Diseases
Current Medicinal Chemistry The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Cancer Drug Targets Profile of HBV Integration in the Plasma DNA of Hepatocellular Carcinoma Patients
Current Genomics Growth Hormone Secretagogue (Ghrelin-) Receptors - A Complex Drug Target for the Regulation of Body Weight
CNS & Neurological Disorders - Drug Targets Perineural Invasion in Adenoid Cystic Carcinoma of the Salivary Glands: Anatomical Influences on Oncological Management
Current Cancer Therapy Reviews Nicotine-Derived Compounds as Therapeutic Tools Against Post-Traumatic Stress Disorder
Current Pharmaceutical Design Role of microRNA Deregulation in Breast Cancer Cell Chemoresistance and Stemness
Current Medicinal Chemistry ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Clinical Efficacy and Effectiveness of Ursodeoxycholic Acid in Cholestatic Liver Diseases
Current Clinical Pharmacology Editorial [Hot Topic: Prospective Clinical Role for Anticancer Garlic Organosulfur Compounds (Guest Editor: Hassan T. Hassan)]
Anti-Cancer Agents in Medicinal Chemistry Molecular Mechanisms Underlying St. Johns Wort Drug Interactions
Current Drug Metabolism Equilibrative Nucleoside Transporters in Fetal Endothelial Dysfunction in Diabetes Mellitus and Hyperglycaemia
Current Vascular Pharmacology Obesity: Current Treatment and Future Horizons
Mini-Reviews in Medicinal Chemistry On the Physiological Role of Cytosolic 5’-nucleotidase II (cN-II): Pathological and Therapeutical Implications.
Current Medicinal Chemistry RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design The Association between Tumor-associated Macrophages and Glioblastoma: A Potential Target for Therapy
Current Pharmaceutical Design